F8 Gene Hemophilia A Genetic Test in UAE | 2,800 AED | DHA-Licensed Facility

Executive Summary & Core Metrics

Core Metrics

Diagnostic Sensitivity: 99.9% via ISO 9001:2015 accredited next‑generation sequencing of the full F8 gene coding region.
Specimen Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold‑Chain Home Collection (available daily 8 AM–11 PM).
Post‑Test Guidance: Telephonic clinical interpretation by a consultant medical geneticist.
Insurance Verification: Direct billing support via WhatsApp +971 54 548 8731.

A mandatory pre‑test genetic counselling session is conducted to document the pedigree of affected family members and to ensure informed consent according to Federal Decree‑Law No. 4 of 2016 on Medical Liability.

Test Overview & Methodology

The F8 gene NGS test analyzes the entire coding region as well as flanking intronic boundaries of the F8 gene to detect pathogenic variants causing Hemophilia A (congenital factor VIII deficiency). This assay delivers a diagnostic sensitivity of 99.9 % and supports definitive diagnosis, carrier detection, and informed family planning for individuals in the UAE.

Methodology: Next‑Generation Sequencing on an Illumina platform with bioinformatic analysis covering single‑nucleotide variants, small insertions/deletions, and copy‑number variations. All variants are confirmed by Sanger sequencing where clinically indicated.

Feature	Our F8 NGS Test	Closest Alternative (Sanger Sequencing)
Precision / Method	Next-Generation Sequencing (full F8 gene)	Limited exon‑targeted Sanger sequencing
Diagnostic Sensitivity	99.9% (detects rare deep intronic variants)	~85–90% (misses non‑targeted regions)
Turnaround Time	3 to 4 Weeks	6 to 8 Weeks (often multi‑step)
Accreditation & License	ISO 9001:2015, DHA‑licensed facility	Variable; often lacks UAE‑specific lab licensure

Physician Insight & Safety Protocols

“The F8 NGS assay provides comprehensive coverage of the F8 locus and can identify causative variants in the majority of patients with Hemophilia A. Nevertheless, results must be interpreted alongside the patient’s bleeding phenotype, factor VIII activity level, and family pedigree. A negative sequencing result does not exclude mild disease, particularly when an acquired inhibitor or alternate coagulation defect is suspected. I recommend every patient receive pre‑ and post‑test genetic counselling to fully understand the implications for themselves and their relatives.”

— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403

Medication Advisory

Important Clinical Notice

Do not discontinue any prescribed anticoagulant, clotting factor concentrate, or haemostatic medication without consulting your treating physician. Genetic testing is an adjunct to clinical management and does not replace ongoing haematological care or emergency treatment for acute bleeding episodes.

Exclusion Criteria & Emergency Red Flags

Safety & Exclusion Criteria

Exclusion: Active major bleeding that requires immediate factor replacement; inability to provide informed consent in compliance with Federal Decree‑Law No. 4 of 2016 on Medical Liability; minors without written parental or guardian consent accompanied by pre‑test genetic counselling.
Emergency Red Flags: Sudden joint swelling with severe pain, symptoms suggestive of intracranial haemorrhage (severe headache, vomiting, altered consciousness), gastrointestinal bleeding (haematemesis, melaena), or any uncontrolled bleeding episode — seek emergency medical attention immediately.

Patient FAQ & Clinical Guidance

1. What is the purpose of the F8 gene NGS test?

This test identifies pathogenic variants in the F8 gene to confirm a diagnosis of Hemophilia A, determine carrier status in at‑risk females, and guide family planning decisions. Results are interpreted in conjunction with factor VIII activity assays and clinical history.

2. How long does it take to receive the results?

Results are typically available within 3 to 4 weeks from the date of sample receipt at our ISO‑accredited laboratory. Urgent cases may be expedited upon clinical request; please contact our genetic counselling team for details.

3. Is the test suitable for children?

Yes, the test can be performed on children with suspected Hemophilia A provided that written parental or guardian consent is obtained and a pre‑test genetic counselling session is completed as required by Federal Decree‑Law No. 4 of 2016 on Medical Liability. The test requires a single blood draw or buccal swab.

4. What sample types are accepted for home collection?

Our VIP mobile phlebotomy service accepts whole blood (EDTA), extracted DNA, or a single blood spot on an FTA card. All specimens are transported under temperature‑controlled cold‑chain conditions. Phlebotomy appointments are available daily from 8 AM to 11 PM.

5. Will my insurance cover this test?

We offer direct billing verification for most UAE‑based health insurance plans. Please forward your policy details via WhatsApp +971 54 548 8731 to receive a coverage assessment prior to sample collection.

UAE Regulatory & Data Privacy Adherence

DNA Labs UAE operates under the regulatory oversight of the Dubai Health Authority (DHA Facility License No. 1143). All genomic data generated through this test is processed and stored in compliance with:

Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) — governing the collection, processing, and transfer of personal genetic data.
Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields — ensuring the security, confidentiality, and integrity of electronic health records and diagnostic information.

No genetic information is shared with third parties without explicit written consent. Patients retain the right to access their raw sequencing data and to request deletion in accordance with applicable regulations.

Clinical & Logistical Metadata

Test Name	F8 Gene (Hemophilia A) Next‑Generation Sequencing (NGS) Test
Price (AED)	2,800 AED
Turnaround Time	3 to 4 Weeks
Sample Type / Matrix	Whole Blood (EDTA), Extracted DNA, or FTA Card
Methodology Used	Next‑Generation Sequencing (NGS) — full F8 gene coding region and intronic boundaries
ICD-10-CM Code	D66 (Congenital factor VIII deficiency)
LOINC Code	21856-0 (F8 gene mutation analysis)
DHA Facility License & Laboratory Address	DHA License No. 1143 — Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE